Accelerated Access Collaborative

Accelerated Access Collaborative
Name	Accelerated Access Collaborative
Type	Public–private partnership
Founded	2018
Location	United Kingdom
Headquarters	London
Key people	NHS England; Department of Health and Social Care; Office for Life Sciences
Area served	United Kingdom
Mission	Speed up patient access to innovation in healthcare

Accelerated Access Collaborative

The Accelerated Access Collaborative is a UK-based public–private partnership established to speed the adoption of health innovations into the National Health Service and related care pathways. It brings together national agencies, industry, regulators and patient groups to coordinate pathways for medicines, devices, diagnostics and digital health. The initiative sits at the intersection of NHS England, the Department of Health and Social Care, and the Office for Life Sciences, working with regulators, funders and industry to shorten the time between regulatory approval and routine clinical use.

History

The Collaborative emerged from policy work following the 2016 publication by the Life Sciences Industrial Strategy and was formally announced during priorities set by ministers in the Theresa May administration. It built on prior mechanisms such as the Accelerated Access Review chaired by Sir John Bell and iterations of the NHS Innovation Accelerator, consolidating efforts across the Medicines and Healthcare products Regulatory Agency and National Institute for Health and Care Excellence. Its launch was influenced by responses to the Biomedical Catalyst funding landscape and strategic goals articulated in successive Industrial Strategy White Paper discussions. Over time, it adapted to pressures from the COVID-19 pandemic, aligning with emergency pathways used by Public Health England and collaborating with the Vaccines Taskforce and other pandemic-era delivery bodies.

Structure and Governance

Governance of the Collaborative is a multi-agency board model that includes senior representatives from NHS England, the Department of Health and Social Care, the Office for Life Sciences, the Medicines and Healthcare products Regulatory Agency, and NHS Confederation-level partners. It convenes working groups and expert panels drawing on members from industry bodies such as the Association of the British Pharmaceutical Industry and regulatory science experts from the National Institute for Health and Care Excellence. Strategic oversight has involved ministers from successive cabinets including those in the Boris Johnson era, and operational links with delivery organisations like NHSX and Health Education England. Commissioned secretariat functions have often been hosted within national agencies and linked to funding streams administered by Innovate UK and UK Research and Innovation.

Objectives and Functions

The Collaborative’s core objective is to reduce barriers between innovation approval and patient access by aligning regulatory, reimbursement and adoption processes across partner institutions. Functions include horizon scanning alongside bodies such as the National Institute for Health Research, providing coordinated advice on evidence generation with input from National Health Service (NHS) Trusts, and designing adoption pathways informed by clinical networks like the Royal Colleges. It seeks to integrate commercial innovation led by firms represented by the BioIndustry Association with health system procurement frameworks, streamline use of expedited routes offered by the Medicines and Healthcare products Regulatory Agency, and inform health technology assessment conducted by National Institute for Health and Care Excellence panels.

Programs and Initiatives

Programmatic work has included priority pathways for high-impact areas such as cancer, rare diseases, and digital diagnostics, building on trial models like the Accelerated Access Pathway and pilots with Genomics England. Initiatives feature matchmaking between innovators and early adopter NHS sites, coordinated by networks similar to the Accelerator Centres and drawing on funding instruments akin to the Small Business Research Initiative. The Collaborative supported deployment programs that mirrored approaches used by the NHS Innovation Accelerator and national procurement pilots run with NHS Supply Chain. During the pandemic it interfaced with rapid evaluation platforms like those developed by ISARIC and trial delivery organisations such as the National Institute for Health Research (NIHR) Clinical Research Network.

Partnerships and Stakeholders

Key stakeholders include national regulators (Medicines and Healthcare products Regulatory Agency), health technology assessment bodies (National Institute for Health and Care Excellence), research funders (UK Research and Innovation, National Institute for Health Research), and NHS delivery organisations (NHS England, Integrated Care Systems). Industry partners span multinational pharmaceutical companies, medtech firms represented by the Association of British HealthTech Industries, and small and medium enterprises supported by Innovate UK. Patient and professional voices have been incorporated through organisations such as Healthwatch England, the Royal College of Physicians, and condition-specific charities including Cancer Research UK and The Wellcome Trust-funded networks.

Impact and Outcomes

The Collaborative reported acceleration of selected products into pilot adoption, facilitation of joint funding awards, and reduced administrative friction among agencies, reflected in case studies involving novel diagnostics and digital health tools adopted by NHS Trusts. It contributed to cross-agency frameworks that informed streamlined evidence requirements and influenced procurement pilots run by NHS Supply Chain. During the COVID-19 pandemic, partnership models it promoted aided scaled deployment of diagnostics and therapeutics under expedited arrangements, interfacing with the Vaccines Taskforce and emergency approval processes. Outcomes also include increased visibility for small firms that gained entry to NHS test-bed sites and national commissioning conversations.

Criticisms and Challenges

Critiques highlight limited transparency in prioritisation decisions and the risk that public–private alignment may favour larger multinational entities represented by bodies like the Association of the British Pharmaceutical Industry over smaller innovators. Observers from think tanks and organisations such as Nuffield Trust and The King’s Fund have noted uneven uptake across regions and variable capacity among Integrated Care Systems to implement pilots. Challenges include aligning disparate evidence standards between the Medicines and Healthcare products Regulatory Agency and National Institute for Health and Care Excellence, securing sustainable funding beyond time-limited pilots, and balancing rapid access with robust evaluation demanded by clinical leaders at organisations like the Royal College of General Practitioners.

Category:Health policy